SYNOPSIS Coagulation studies were performed on nine children with burns. Four of these children received treatment which included intravenous dextran; all four showed abnormalities of coagulation and two of them developed a bleeding state. No abnormalities of haemostasis were detected in the remaining five children who had comparable degrees of burns but whose treatment did not include intravenous dextran.
Our attention was first drawn to a disturbance of coagulation following burns in a 2-year-old child (Table, case 1). He began to bleed profusely from the sites of injury two days after suffering a scald involving 25% of his body surface (Fig. 1) . During the 48 hours following the burn fluid was administered intravenously in the form of dextran (Dextravent 110 and 150) and half-strength Hartman's solution, as calculated from the fluid regime described in the addendum. The results of coagulation studies are shown in the Table (case 1) . A diagnosis of disseminated intravascular coagulation was considered likely. At the time of the bleeding, swabs taken from the burned area showed no bacterial growth. As septicaemia is a recognized cause of disseminated intravascular coagulation, blood cultures were taken but no significant microbial growth occurred.
Heparin therapy was started by continuous intravenous infusion (100 units/kg/six hours). The subsequent changes are shown in Figure 2 . These results are evidence that the disorder of coagulation was corrected. The bleeding stopped within 12 hours of starting heparin and the patient returned home 10 days later without requiring a skin graft. We afterwards observed that the onset of heparin therapy had coincided with the withdrawal of dextran.
Generalized spontaneous bleeding is extremely unusual as a complication of burns, except as a result of secondary infection. No reference is made to such events in current editions of standard textbooks (Sevitt, 1957; Biggs and MacFarlane, 1962; Hardisty (Pitney, 1971) . The changes in coagulation factors and platelets have been studied after cutaneous burns in human subjects (MacDonald, Levenson, Davidson, Tagnon, and Taylor, 1944) and in experimental animals (Dodd-Wilson, Taylor, and Nicholson, 1965; Mazak, Vanasek, and Mateja, 1965) . Shortly after an extensive burn clotting systems are accelerated (Sevitt, 1957) . In subjects who die within hours or a few days of severe burns, disseminated microthrombi are frequently found. These findings may be the counterpart of a consumption coagulopathy. Nevertheless bleeding is an unusual problem in clinical experience.
In view of these observations we believe that the clinical and laboratory findings which follow may be of some interest.
Coagulation Studies in Other Burned Children
Because of the unexpected bleeding in an otherwise uncomplicated case of burns, clotting studies were performed in eight children with bums who were admitted to Guy's Hospital. Abnormalities of clotting were found in three of these children (cases 2, 3, and 5) all of whom had received dextran: case 3 bled considerably for a number of days from the site of a femoral vein puncture. No abnormalities of clotting were found in the remaining five patients, Trevor Thomas, Arthur Morris, and Michael S. Rose none of whom had received dextran (cases 4, 6, 7, 8, and 9) . Details are shown in the Table. Case 4, with 13 % bums, was given neither dextran nor plasma, and cases 6-9, with burns between 140% and 30 %, received plasma and no dextran. In case 5, samples were tested before, during, and after the administration of dextran, and the sequence of events is illustrated in Figure 3 .
In-vitro Effect of Dextran on Coagulation and Platelets
Standard coagulation tests (Hardisty and Ingram, 1965) were then measured in these mixtures. Control measurements were made upon plasma-dextrose mixtures.
The aggregating effects of dextran on platelets were studied by mixing platelet-rich plasma in equal parts with dilutions of dextran in dextrose. Samples were incubated for 30 minutes at 37°C. They were then examined microscopically.
Results
The addition of dextran was found to have no effect on the prothrombin or kaolin-cephalin times. However the addition of a 50% dextran solution was responsible for shortening the thrombin time from 12 seconds to 8 seconds.
The addition of dextran to plasma did not shorten the partial thromboplast time.
Dilutions between 12-5 and 50 % of the 6 % dextran solution caused aggregation of platelets after 30 minutes at 37°C whereas aggregation was not observed after incubation with dextrose.
Discussion
Dextran preparations are widely employed in the early treatment of severe burns with fluids. A limited enquiry from burns units in the vicinity of London has made it clear that bleeding problems in subjects receiving dextran have not been encountered. But although the laboratory findings described above could have been a consequence of the burns (MacDonald et al, 1944; Johansson, 1961 and Arturson and Wallenius, 1964; Hawtof, 1966) it seems more likely that the administration of dextran produced the coagulation abnormalities and the fall in platelets. Certainly, at least, the concentration of dextran employed in the in vitro test systems corresponded closely to the in vivo dextran concentrations which were present during and shortly after colloid replacement treatment (see addendum).
The effects of dextran upon platelets and clotting factors are partly determined by its molecular size (Nilssen and Eiken, 1964) . Our observations are similar to those of Dhall, Harper, McKenzie, and Matheson (1966) who demonstrated that dextrans ranging in molecular weight from 10 000 to 500 000 caused aggregation of human platelets in vivo. Berman (1964) showed that dextran inhibits platelet aggregation in vivo at sites of injury in the hamster cheek pouch. Others have shown that dextran infusion into healthy human subjects reduces platelet adhesiveness (Bygdeman and Eliasson, 1966; Bennett, Dhall, McKenzie, and Matheson, 1966) . Possibly these discordant findings can be explained by the sequestration in vivo of clumped platelets after dextran infusion, leaving a residual circulating population of platelets with uncharacteristic activity. However, Bennett et al (1966) did not note any substantial change in the venous platelet count of their subjects within 24 hours of dextran infusion. Bergentz, Eiken, and Nilssen (1961) found that infusion of high-molecular weight dextran into dogs caused thrombocytopenia, fibrinogenopenia, and depletion of other coagulation proteins. Heparin prevented all of these effects apart from the thrombocytopenia. If these effects of dextran represented a true consumption coagulopathy, heparin would be expected to prevent thrombocytopenia. Furthermore the rate at which the platelet count returned to normal in case 1 after heparin therapy is unusually rapid for this syndrome.
We found no evidence that dextran either inhibited or activated coagulation in vitro. However, we found a striking shortening of the 'thrombin time' both in the plasma of patients transfused with dextran and in normal plasma mixed with dextran. This 'fibrinoplastic' effect has been previously described by Laurell (1951) and Jacobaeus (1955) .
Working with dogs, Nilssen and Eiken (1964) showed that the molecular weight of the dextran was the main factor in determining the degree to which coagulation was impaired. They argued that the administration of high molecular weight dextran causes a consumption coagulopathy. We are inclined to explain our findings as the result of independent effects of dextran upon coagulation factors and platelets. It is intriguing that dextran is responsible for a shortened thrombin time both in vivo and in vitro, and correspondingly accelerates the final steps in clot formation, whereas its other effects in vivo are inclined to produce impaired clotting. Whatever the sequence of events, it is clear that a reduction in coagulation and a fall in platelets frequently accompanies the administration of high-molecular weight dextrans.
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